MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Non-motor Scales"

  • 2022 International Congress

    Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson´s Disease: An Open-label Prospective Study

    D. Santos García, G. Fernández Pajarín, J. Oropesa Ruíz, F. Escamilla Sevilla, R. Rahim Lopez, G. Muñoz Enríquez (A Coruña, Spain)

    Objective: The aim of this study was to analyze the effectiveness of opicapone on global non-motor symptoms (NMS) burden in Parkinson´s disease (PD). Background: Some…
  • 2022 International Congress

    Blood biomarkers and their association with non-motor symptoms in early Parkinson’s Disease

    J. Kaur, S. Ng, N. Chia, X. Deng, J. Tan, X. Choi, D. Heng, Z. Xu, K. Tay, W. Au, A. Ng, E. Tan, L. Tan (central, Singapore)

    Objective: To identify if baseline blood biomarkers are associated with non-motor symptoms in early PD. Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder with…
  • 2022 International Congress

    Quality of life changes after subthalamic stimulation for Parkinson’s disease depend on nonmotor and motor symptoms clusters

    L. Braun, S. Jost, M. Silverdale, A. Rizos, M. Santos Ghilardi, R. Cury, P. Loehrer, C. Nimsky, K. Ashkan, A. Sauerbier, A. Gronostay, G. Fink, M. Barbe, J. Evans, V. Visser-Vandewalle, E. Fonoff, A. Antonini, L. Timmermann, P. Martinez-Martin, K. Chaudhuri, H. Dafsari (Cologne, Germany)

    Objective: To analyze quality of life (QoL) changes after subthalamic stimulation (STN-DBS) based on a short list of baseline nonmotor and motor symptoms in Parkinson’s…
  • 2022 International Congress

    Mindfulness based program for newly diagnosed Parkinson’s patients.

    A. Shaji, A. Lasker, N. Ko, M. Solanki, P. Kaur, Y. Ocasio, C. Fanning (Bethlehem, USA)

    Objective: To investigate the impact of 8-week course of Mindfulness based intervention program on motor and or non-motor symptoms of PD assessed by improvement in…
  • 2022 International Congress

    The relationship of non-motor symptoms in Parkinson’s disease

    E. Golchenko, Y. Karakulova (Perm, Russian Federation)

    Objective:  Evaluation of non-motor symptoms in patients with Parkinson's disease, evaluation of the relationship of autonomic and neuropsychiatric disorders. Background: This work included a comprehensive…
  • 2022 International Congress

    Liraglutide once daily versus placebo in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial

    T. Wu, C. Bresee, J. Wertheimer, E. Hogg, C. Malatt, E. Tan, H. Pomeroy, G. Obialisi, M. Tagliati (Los Angeles, USA)

    Objective: To test safety and efficacy of the glucagon-like peptide 1 (GLP-1) agonist liraglutide in idiopathic Parkinson’s disease (PD). Background: Insulin resistance (IR) may play…
  • 2022 International Congress

    Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study

    C. Liguori, C. de Masi, M. Spanetta, M. Fernandes, R. Cerroni, E. Garasto, M. Pierantozzi, N. Mercuri, A. Stefani (Rome, Italy)

    Objective: The present study aimed to explore the effect of safinamide treatment on NMS and quality of life in motor-fluctuating PD patients. Background: Parkinson’s disease…
  • 2022 International Congress

    Basal forebrain contribution to cognitive deficits during medication “off” state in Parkinson’s disease

    D. Lench, T. Turner, E. Woolbright, F. Rodriguez-Porcel, G. Revuelta (Charleston, USA)

    Objective: We sought to determine whether structural integrity of cholinergic Basal Forebrain (BF) was associated with subjective cognitive deficits experienced during medication “off” time Parkinson’s…
  • 2022 International Congress

    Frequency of non-motor symptoms in GBA-PD may differ in carriers of mild vs. severe pathogenic variants

    T. Usnich, N. Brüggemann, M. Olmedillas, N. Schell, I. Csoti, S. Ertan, D. Gruber, S. Zittel, E. Sammler, S. Isaacson, A. Kühn, D. Pedrosa, K. Reetz, A. Sah, M. Kasten, P. Bauer, C. Klein (Lübeck, Germany)

    Objective: Parkinson's disease (PD) patients with pathogenic variants in the GBA (glucocerebrosidase) gene (GBA-PD) were reported to exhibit a younger age at onset, faster progression…
  • MDS Virtual Congress 2021

    Lateralization of cochlear dysfunction as a specific biomarker of Parkinson’s disease; role for cholinergic transmission?

    R. Cerroni, A. Viziano, A. Stefani, R. Sisto (Rome, Italy)

    Objective: To understand to what extent an early cochlear dysfunction may represent an additional non-motor signature of Parkinson’s disease (PD) patients. Further, whether it may…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 55
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley